Media
Welcome to the BioMendics media center. BioMendics is advancing innovative science and developing new therapeutic options for people with rare dermatologic disorders. Learn more about our recent work below.
For specific inquiries, please Contact Us.
BioMendics was just featured in Life Sciences Reviews Vendor ViewPoint this follows our receipt of Top Rare Dermatologic Disorders Medication Development 2025
BioMendics is headed to JP Morgan Healthcare Conference in San Francisco. We will be attending the Dermatology Summit on January 11th, 2026 and presenting at the Biotech Showcase on January 12th, 2026 @ 2:30pm PT.
Please find our latest press release here.
The press release titled: BioMendics Brings New Hope for Epidermolysis Bullosa Simplex Patients as TAMES‑02 Trial Advances and JPM Week Approaches was also covered here:
Biospace:https://www.biospace.com/press...
Yahoo Finance: https://finance.yahoo.com/news...
Marketwatch: https://www.marketwatch.com/pr...
To learn more about the TAMES-02 clinical trial check out this BioMendics Press Release
The TAMES-02 study launch was also covered here:
Dermatology Times: https://www.dermatologytimes.com/view/tames-02-trial-launches-for-eb-simplex-therapy
Yahoo Finance:https://finance.yahoo.com/news...
Associated Press: https://apnews.com/press-relea...
Boston Herald: https://markets.financialconte...
Wellness Insider: https://thewellnessinsider.asi...
MedPath: https://trial.medpath.com/news...
BioMendics Received Top Rare Dermatologic Disorders Medication Development 2025 from Life Sciences Review
Life Sciences Review: https://www.lifesciencesreview...